A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

Inclusion Criteria:

* Males or females aged 18 to 55 years old (inclusive) at the time of signing the informed consent form.
* Standard contraception measures are required for this clinical trial.
* Healthy, in the opinion of the Investigator, based on prior (history of) or current (ongoing) medical and psychiatric screening assessments.
* Participants with no clinically significant findings on physical examination, laboratory tests, and cardiac assessment.
* Body mass index (BMI) within the range 18-32 kg/m2, inclusive.
* Normal blood pressure.
* Willing to not operate heavy machinery, including driving a vehicle at least 36 hours post Day 1 dose administration and 24 hours post all other dose administrations.
* Capable of giving signed informed consent which includes the requirements and restrictions as per the approved study protocol

Exclusion Criteria:

* Prior known exposure to psilocybin, LSD, ayahuasca, N, N-Dimethyltryptamine, and related tryptamines, within the past 5 years.
* Prior (history of) or current (ongoing) diagnosis, or first-degree relatives with clinically significant medical or psychiatric condition or disease.
* History of non-hospitalized but medicated Major Depressive Disorder (MDD), Generalized Anxiety Disorder or Panic Disorder ≤ 5 years prior to Screening.
* History of or presence of cardiovascular disease.
* Abnormal and clinically significant ECG.
* Known personal or family history of congenital long QT syndrome or sudden death.
* Current or a history of orthostatic hypotension or postural orthostatic tachycardic syndrome, multiple syncopes, or unresolved/ongoing clinically significant hypotensive episodes or symptoms of fainting, dizziness, or light-headedness.
* History or presence of a neurodegenerative disorder such Alzheimer's disease or Parkinson's disease or other behavioral disturbances resulting from other neurological disorders.
* Use of medications that have CNS effects or affect performance.
* Use of medications with serotonergic activity.
* History or presence of hypersensitivity or idiosyncratic reaction to psilocybin or related compounds or microcrystalline cellulose
* History of substance or alcohol abuse disorder in the last 10 years.
* Participant who, for any reason, is deemed by the Investigator to be inappropriate for this study.
* Contraindications to magnetic resonance imaging (MRI) or fMRI.